PROMIS NEUROSCIENCES INC. Unrealized Gain (Loss) on Derivatives
PROMIS NEUROSCIENCES INC. (PMN) reported Unrealized Gain (Loss) on Derivatives of $5.59 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-03-25
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for the quarter ending 2024-12-31 was $5.57M, a 2939.47% increase year-over-year.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for the quarter ending 2023-12-31 was $183.17K.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for the quarter ending 2022-12-31 was -$92.25K, a 105.54% decline year-over-year.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for fiscal 2025 was $5.59K, a 99.98% decline from fiscal 2024.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for fiscal 2024 was $22.58M, a 2505.34% increase from fiscal 2023.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for fiscal 2023 was $866.74K, a 66.02% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. unrealized gain (loss) on derivatives for fiscal 2022 was $2.55M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.59K 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $22.58M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $17.01M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $183.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $866.74K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $683.57K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | -$92.25K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$92.25K derived: sum of 2 quarters · filed 2024-04-01 | $814.77K derived: sum of 3 quarters · filed 2024-04-01 | $2.55M 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $907.01K derived: sum of 2 quarters · filed 2023-11-14 | $2.64M 10-Q · filed 2023-11-14 | $4.31M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $907.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.64M 10-Q · filed 2023-08-14 | $4.31M derived: sum of 3 quarters · filed 2023-08-14 | $5.23M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.74M 10-Q · filed 2023-05-15 | $3.40M derived: sum of 2 quarters · filed 2023-05-15 | $4.32M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $2.59M derived: sum of 2 quarters · filed 2023-03-08 | -$1.94M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $922.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$3.60M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$4.52M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |